High-amylose carboxymethyl starch matrices for oral sustained drug-release
High-amylose corn starch, that contains 70% of amylose chains and 30% of amylopectin, has been used to obtain substituted amylose (SA) polymers. Tablets have been prepared by direct compression, i.e. dry mixing of drug and SA, followed by compression, which is the easiest way to manufacture an oral...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , |
| Format: | article |
| Published: |
2016
|
| Online Access: | http://hdl.handle.net/10725/4593 http://dx.doi.org/10.1016/j.ejpb.2006.12.001 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://www.sciencedirect.com/science/article/pii/S0939641106003511 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513464040423424 |
|---|---|
| author | Nabais, T. |
| author2 | Brouillet, F. Kyriacos, S. Mroueh, M. Amores da Silva, P. Bataille, B. Chebli, C. Cartilier, L. |
| author2_role | author author author author author author author |
| author_facet | Nabais, T. Brouillet, F. Kyriacos, S. Mroueh, M. Amores da Silva, P. Bataille, B. Chebli, C. Cartilier, L. |
| author_role | author |
| dc.creator.none.fl_str_mv | Nabais, T. Brouillet, F. Kyriacos, S. Mroueh, M. Amores da Silva, P. Bataille, B. Chebli, C. Cartilier, L. |
| dc.date.none.fl_str_mv | 2016-10-13T10:04:23Z 2016-10-13T10:04:23Z 2016-10-13 |
| dc.identifier.none.fl_str_mv | 0939-6411 http://hdl.handle.net/10725/4593 http://dx.doi.org/10.1016/j.ejpb.2006.12.001 Nabais, T., Brouillet, F., Kyriacos, S., Mroueh, M., Da Silva, P. A., Bataille, B., ... & Cartilier, L. (2007). High-amylose carboxymethyl starch matrices for oral sustained drug-release: in vitro and in vivo evaluation. European Journal of Pharmaceutics and Biopharmaceutics, 65(3), 371-378. http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://www.sciencedirect.com/science/article/pii/S0939641106003511 |
| dc.language.none.fl_str_mv | en |
| dc.relation.none.fl_str_mv | European Journal of Pharmaceutics and Biopharmaceutics |
| dc.rights.*.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.title.none.fl_str_mv | High-amylose carboxymethyl starch matrices for oral sustained drug-release In vitro and in vivo evaluation |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | High-amylose corn starch, that contains 70% of amylose chains and 30% of amylopectin, has been used to obtain substituted amylose (SA) polymers. Tablets have been prepared by direct compression, i.e. dry mixing of drug and SA, followed by compression, which is the easiest way to manufacture an oral dosage form. Until now, their controlled-release properties have been assessed only by an in vitro dissolution test. Amylose-based polymers are normally subject to biodegradation by α-amylase enzymes present in the gastrointestinal tract, but matrix systems show no significant degradation of tablets by α-amylase in vitro. High-amylose sodium carboxymethyl starch (HASCA) is an interesting excipient for sustained drug-release in solid oral dosage forms. In addition to the easy manufacture of tablets by direct compression, the results show that in vitro drug-release from an optimized HASCA formulation is not affected by either acidic pH value or acidic medium residence time. In addition, a compressed blend of HASCA with an optimized quantity of sodium chloride provides a pharmaceutical sustained-release tablet with improved integrity for oral administration. In vivo studies demonstrate extended drug absorption, showing that the matrix tablets do not disintegrate immediately. Nevertheless, acetaminophen does not seem to be the most appropriate drug for this type of formulation. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | LAURepo_937a2717680b07ec7b9dc8b340ff438c |
| identifier_str_mv | 0939-6411 Nabais, T., Brouillet, F., Kyriacos, S., Mroueh, M., Da Silva, P. A., Bataille, B., ... & Cartilier, L. (2007). High-amylose carboxymethyl starch matrices for oral sustained drug-release: in vitro and in vivo evaluation. European Journal of Pharmaceutics and Biopharmaceutics, 65(3), 371-378. |
| language_invalid_str_mv | en |
| network_acronym_str | LAURepo |
| network_name_str | Lebanese American University repository |
| oai_identifier_str | oai:laur.lau.edu.lb:10725/4593 |
| publishDate | 2016 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| spelling | High-amylose carboxymethyl starch matrices for oral sustained drug-releaseIn vitro and in vivo evaluationNabais, T.Brouillet, F.Kyriacos, S.Mroueh, M.Amores da Silva, P.Bataille, B.Chebli, C.Cartilier, L.High-amylose corn starch, that contains 70% of amylose chains and 30% of amylopectin, has been used to obtain substituted amylose (SA) polymers. Tablets have been prepared by direct compression, i.e. dry mixing of drug and SA, followed by compression, which is the easiest way to manufacture an oral dosage form. Until now, their controlled-release properties have been assessed only by an in vitro dissolution test. Amylose-based polymers are normally subject to biodegradation by α-amylase enzymes present in the gastrointestinal tract, but matrix systems show no significant degradation of tablets by α-amylase in vitro. High-amylose sodium carboxymethyl starch (HASCA) is an interesting excipient for sustained drug-release in solid oral dosage forms. In addition to the easy manufacture of tablets by direct compression, the results show that in vitro drug-release from an optimized HASCA formulation is not affected by either acidic pH value or acidic medium residence time. In addition, a compressed blend of HASCA with an optimized quantity of sodium chloride provides a pharmaceutical sustained-release tablet with improved integrity for oral administration. In vivo studies demonstrate extended drug absorption, showing that the matrix tablets do not disintegrate immediately. Nevertheless, acetaminophen does not seem to be the most appropriate drug for this type of formulation.PublishedN/A2016-10-13T10:04:23Z2016-10-13T10:04:23Z2016-10-13Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article0939-6411http://hdl.handle.net/10725/4593http://dx.doi.org/10.1016/j.ejpb.2006.12.001Nabais, T., Brouillet, F., Kyriacos, S., Mroueh, M., Da Silva, P. A., Bataille, B., ... & Cartilier, L. (2007). High-amylose carboxymethyl starch matrices for oral sustained drug-release: in vitro and in vivo evaluation. European Journal of Pharmaceutics and Biopharmaceutics, 65(3), 371-378.http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.phphttp://www.sciencedirect.com/science/article/pii/S0939641106003511enEuropean Journal of Pharmaceutics and Biopharmaceuticsinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/45932024-01-29T14:24:33Z |
| spellingShingle | High-amylose carboxymethyl starch matrices for oral sustained drug-release Nabais, T. |
| status_str | publishedVersion |
| title | High-amylose carboxymethyl starch matrices for oral sustained drug-release |
| title_full | High-amylose carboxymethyl starch matrices for oral sustained drug-release |
| title_fullStr | High-amylose carboxymethyl starch matrices for oral sustained drug-release |
| title_full_unstemmed | High-amylose carboxymethyl starch matrices for oral sustained drug-release |
| title_short | High-amylose carboxymethyl starch matrices for oral sustained drug-release |
| title_sort | High-amylose carboxymethyl starch matrices for oral sustained drug-release |
| url | http://hdl.handle.net/10725/4593 http://dx.doi.org/10.1016/j.ejpb.2006.12.001 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://www.sciencedirect.com/science/article/pii/S0939641106003511 |